Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Acquisitions & Divestments (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Change in Acquisitions & Divestments data on record, last reported at $22.7 million in Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments fell 42.09% year-over-year to $22.7 million; the TTM value through Sep 2025 reached $117.8 million, up 2.28%, while the annual FY2024 figure was $130.7 million, 101.03% up from the prior year.
  • Change in Acquisitions & Divestments reached $22.7 million in Q3 2025 per ASMB's latest filing, down from $34.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $39.5 million in Q2 2022 and bottomed at $3.0 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $22.3 million, with a median of $21.7 million recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 70.0% in 2021, then surged 147.87% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $9.5 million in 2021, then soared by 131.58% to $22.0 million in 2022, then dropped by 15.0% to $18.7 million in 2023, then skyrocketed by 82.89% to $34.2 million in 2024, then plummeted by 33.63% to $22.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $22.7 million in Q3 2025, $34.5 million in Q2 2025, and $26.4 million in Q1 2025.